logo-loader

AstraZeneca sells rights for constipation drug to RedHill Biopharma

Published: 08:46 25 Feb 2020 GMT

AstraZeneca - AstraZeneca sells rights for constipation drug to RedHill Biopharma

 

AstraZeneca PLC (LON:AZN) has sold the rights to its drug Movantik to RedHill Biopharma for US$67mln.

The treatment, used in patients suffering from constipation caused by painkillers, generated sales of US$96mln in the US alone last year.

 

READ: AstraZeneca revenues surge ahead but coronavirus clouds current year

The FTSE 100-listed firm has already divested the rights to sell the drug in Europe, Canada and Israel while the transaction, scheduled to complete in the first quarter, is not expected to hit guidance for 2020.

“This divestment supports our strategy to realise value from medicines in our portfolio that are mature or outside our current scope to enable reinvestment in our main therapy areas,” said Ruud Dobber, executive vice president at AstraZeneca’s biopharmaceuticals business unit.

Shares were flat at 7,416p on Tuesday morning.

HANetf founder and co-CEO discusses shift to active management in ETF market

HANetf founder and co-CEO Hector McNeil tells Proactive's Stephen Gunnion about shifting trends in the exchange-traded fund (ETF) market in the United States, indicating a big move towards active management within ETFs. Despite the European market lagging behind the US by three to five years,...

15 hours, 14 minutes ago